Addressing this autoimmune disorder characterized by thrombosis or pregnancy morbidity coupled with persistent antiphospholipid antibodies involves identifying and mitigating thrombosis risk factors.
The November 2023 ACC/AHA/ACCP/HRS release suggests early, aggressive rhythm control and provides parameters for pausing or stopping therapies, among other recommendations.
Along with recent guidelines, pharmacists can use their skills to improve outcomes in these patients, such as ensuring appropriate medication timing and administration.
Multidisciplinary collaboration coupled with the use of multimodal strategies has enabled the tailoring of treatment plans based on the patient’s medical status and type of surgery.